Haematitum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a mineral-origin active pharmaceutical ingredient whose pharmacopoeial identity is expressed as total iron oxide rather than as a defined stoichiometric hydrate. The principal crystalline phase is α-Fe₂O₃ (CAS 1309-37-1), accompanied by naturally occurring siliceous and aluminosilicate gangue that is partially removed by acid washing and elutriation. Manufacturer model codes are dosage-route specific: HMT-V-325 identifies oral solid dosage material with a D90 not exceeding 45 µm; HMT-V-10M identifies injectable-grade micronized material with a D90 not exceeding 10 µm; HMT-V-150P identifies premix and powder feed material with a D90 not exceeding 150 µm. The Chinese Pharmacopoeia 2020 crude mineral monograph for Haematitum sets a minimum Fe₂O₃ assay of 45.0%; refined veterinary API grades commonly operate within a 60.0% to 85.0% Fe₂O₃ window, with the upper bound reserved for injectable formulations. The API is intended for direct incorporation into tablets, hard gelatin or HPMC capsules, powders, granules, medicated premixes, oral suspensions, and acid-derived ferric solutions; it is not a soluble ferrous salt and does not behave as such during compendial dissolution testing.

The beneficiation route for HMT-V grades includes dry magnetic separation, dilute hydrochloric acid washing, neutral water rinsing, belt drying, and air-jet milling. Injectable-grade HMT-V-10M receives additional depyrogenation and endotoxin retest after micronization. Batch certificates of analysis list assay, loss on drying, acid-insoluble matter, elemental impurities, particle-size distribution, and microbiological burden as separate line entries.

What Distinguishes Veterinary-Use Haematitum from Technical Hematite and Food-Grade E172?

Separation between the veterinary API and technical iron oxide is established by elemental impurity limits, particle-size control, and microbiological specification. Technical hematite used in pigments and polishing compounds may contain acid-extractable lead, arsenic, and cadmium at concentrations that exceed compendial thresholds, and its particle-size distribution is optimized for color strength or lapping performance rather than blend uniformity or syringeability. Food-grade iron oxide red (E172) is controlled for dye purity under food additive criteria, but its specification does not include endotoxin limits, injectable particulate matter limits, or veterinary pharmacopoeial assay identity. The veterinary API is tested using USP <232> and USP <233> or equivalent VICH/ICH-derived methods, with representative contract limits of lead ≤ 10 ppm, arsenic ≤ 5 ppm, cadmium ≤ 3 ppm, and mercury ≤ 1 ppm for oral solid grades; injectable grades tighten arsenic to ≤ 2 ppm and lead to ≤ 5 ppm. Loss on drying at 105 °C for 2 h is typically controlled to ≤ 0.5% for oral and premix grades and ≤ 0.2% for injectable material. Natural haematite may contain magnetite intergrowths that increase magnetic susceptibility; veterinary-grade material is passed through high-gradient magnetic separation to remove ferrimagnetic contaminants that would otherwise complicate uniform mixing and analytical sampling. The mineral also differs from synthetic red iron oxide in surface chemistry: natural haematite retains trace aluminosilicate functionality that can alter wetting and suspension pH in aqueous media.

The mineral source is controlled by geological origin and lot identity. Because natural haematite composition can vary, blending of ore lots before acid washing is used to reduce batch-to-batch variance. Stability of the dry mineral is high, but high-humidity exposure can increase loss on drying and microbial growth, so retesting after storage at relative humidity above 60% is standard.

For tablet and capsule applications, specification control concentrates on particle-size distribution, flowability, and the fraction of acid-insoluble matter. A D90 of 45 µm is a practical upper limit because coarser particles segregate during low-shear mixing and create content-uniformity failures in direct compression blends. Particle-size distribution is measured by laser diffraction or by USP <786> analytical sieving, and the D10–D90 span is often held below 2.5 to avoid multimodal packing defects. Powder flow is characterized by USP <1174>; haematitum-containing direct compression blends with a Hausner ratio above 1.25 are usually unsuitable without glidant addition or wet granulation. The mineral does not deform plastically under typical tableting pressures, so wet granulation with a binder such as povidone or hydroxypropyl cellulose is preferred over direct compression at high drug loading. Magnesium stearate is used at 0.5–1.0% w/w; prolonged mixing beyond 5 minutes should be avoided because hydrophobic lubrication can reduce tensile strength. Tablet hardness, disintegration per USP <2040>, and dissolution per USP <711> are run as finished-product tests; however, dissolution data for crystalline Fe₂O₃ must be interpreted with pH-specific iron solubility in mind. Release of soluble iron from the raw mineral in compendial media is low unless the formulation includes an acidifying excipient or the method uses a defined acid stage. Acid-insoluble matter is tested after hydrochloric acid digestion and is generally controlled to ≤ 5.0% for oral grades; elevated values indicate incomplete beneficiation of silicate gangue and can increase tablet tooling wear.

When the API Is Destined for Injectable Suspensions or Acid-Derived Solutions

Injectable use imposes the tightest particle-size and bioburden constraints. The micronized grade HMT-V-10M is controlled to a D90 ≤ 10 µm and a D50 typically in the 1–3 µm range, because larger particles can obstruct 21-gauge or 23-gauge needles and contribute to particulate matter failures. The suspension is tested for subvisible particles by USP <788>; limits for large-volume parenterals are ≤ 25 particles/mL at ≥ 10 µm and ≤ 3 particles/mL at ≥ 25 µm, while small-volume injectables use container-based limits of 6000 and 600 particles per container, respectively. The API is depyrogenated by dry heat; a parenteral monograph or marketing authorization may require a bacterial endotoxin limit of ≤ 0.5 EU/mg using USP <85> or equivalent. Sterility is not an API property but is required for the finished injectable; the API is supplied with bioburden below 100 CFU/g and specified absence of Gram-negative pathogens. Autoclaving mineral suspensions can promote aggregation; dry heat depyrogenation of the API followed by aseptic compounding is therefore preferred over terminal sterilization of the suspension where particle-size stability is critical. Haematitum is practically insoluble in water at neutral pH; therefore the term “solution” applies only after acid digestion to ferric salts or formulation in acidified media. Published production-scale data for haematitum injectable suspensions is limited; process development therefore relies on compendial particle-size, endotoxin, and sterility methods rather than on robust pharmacokinetic datasets.

Solution-type formulations require conversion of the oxide to a soluble ferric salt; acid digestion with hydrochloric acid is controlled by stoichiometric acid demand and residual insoluble matter. The resulting ferric chloride solution is pH-dependent and corrosive to stainless steel unless diluted or passivated. Published data for this specific configuration is limited; manufacturers determine endpoint by batch-specific acid consumption and residual solid content rather than a fixed acid volume.

Premix and powder feed applications tolerate a coarser particle size but impose different segregation risks. The HMT-V-150P material has a D90 ≤ 150 µm, which aligns with sieve cuts used in medicated feed premixes and reduces dusting during open transfer. Bulk density of mineral haematitum is approximately 5.26 g/cm³ for the compact solid, but loose bulk densities in the 1.8–2.6 g/cm³ range are typical for milled powders; the large density differential relative to cornmeal or calcium carbonate diluents makes gravitational segregation possible in bulk bins. Production-scale premix blending is therefore performed with a stepwise dilution sequence, and the coefficient of variation for iron content in feed mill samples is monitored by ICP-OES or atomic absorption. Granules produced by wet granulation with the API should be dried to moisture ≤ 0.5% to prevent caking during storage; if the API is added to a mineral premix containing calcium carbonate, magnesium oxide, or dicalcium phosphate, blend pH may drift upward and reduce soluble iron release in acid-fed animals. This interaction is not a compatibility failure in all cases, but it should be evaluated by a forced degradation study at 40 °C/75% RH for 6 months if the premix is registered as a medicated article. For powders, the API is passed through a 0.425 mm sieve before blending to remove agglomerates formed during storage. Granule sieve fractions between 0.180 mm and 0.850 mm are common for veterinary oral dispensing. The red-brown color of the oxide is used as a visual homogeneity aid in feed mills, but quantitative verification remains ICP-OES or atomic absorption because color contrast may be masked by other mineral feed ingredients.

Tabletting without Tooling Damage Requires More Than Particle-Size Reduction.

The α-Fe₂O₃ phase has Mohs hardness of 5.5–6.5, which is the primary concern for tablet compression and capsule filling equipment. Rotary tablet presses with standard B-tooling can exhibit punch-tip abrasion when haematitum exceeds 30% of the core weight and the granulation is not adequately lubricated. Tablet manufacturers often use chromium-nitride or diamond-coated punch tips, and they run precompression in the 5–8 kN range to consolidate the granulation before main compression. Compression force must be balanced because the brittle mineral/agglomerate system consolidates by fracture rather than plastic flow; overcompression can generate capping at hardness values above 12–15 kp for convex tablets. Capsule filling on dosator or tamping-type machines is affected by powder flow; blends with Hausner ratio above 1.20 may require glidant addition or slugging. In high-shear wet granulation, the endpoint is controlled by impeller power consumption rather than fixed water volume, because the mineral has low binder demand and can overmass within a narrow liquid-addition window. Production-scale batches are often granulated with a top-spray fluid-bed dryer or a high-shear mixer with integrated wet mill; published data for specific equipment settings for haematitum are limited, so process qualification uses batch-specific torque curves and granule size distribution. Tooling wear can be monitored by punch-tip profilometry; replacement intervals are dictated by measured wear rather than visual inspection.

Route-Dependent Specification Limits and Pharmacopoeial Test Methods

The following matrix comprises representative acceptance limits used in contract specifications; these are not universally harmonized pharmacopoeial requirements for every regulatory jurisdiction.

Compared with technical hematite, food-grade E172, and soluble ferrous salts, the veterinary API occupies a separate regulatory and formulation category. Technical hematite should not be substituted because its heavy metal profile and broad particle-size distribution are not controlled for ingestion or injection. Food-grade E172 is not tested for endotoxin or injectable particulate matter and does not carry a pharmacopoeial assay identity for mineral drug use. Soluble ferrous salts such as ferrous sulfate heptahydrate provide rapid iron release but differ in stability, pH behavior, and compatibility with oxidizing excipients; haematitum remains a slowly acid-soluble iron source with a crystalline oxide matrix.